Epiphany, a San Francisco biotech company focused on developing anti-infective agents, said it has raised a $36 million first round of financing.

Wexford Capital, LLC led the financing, which included Windsor Bay Capital, Global Trust Ventures Management, CDIB BioScience Venture Management (CBVM) and several private investors.

One of its first products is a treatment for shingles.

Here is the announcement.